Cargando…
Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer
Raloxifene (RLX) is a second-generation selective estrogen receptor modulator approved for the prevention of invasive breast cancer in women. Oral therapy of RLX requires daily intake and is associated with side effects that may lead to low adherence. We developed a weekly transdermal delivery syste...
Autores principales: | Vora, Deepal, Dandekar, Amruta, Bhattaccharjee, Sonalika, Singh, Onkar N., Agrahari, Vivek, Peet, M. Melissa, Doncel, Gustavo F., Banga, Ajay K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953220/ https://www.ncbi.nlm.nih.gov/pubmed/35336054 http://dx.doi.org/10.3390/pharmaceutics14030680 |
Ejemplares similares
-
Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV
por: Puri, Ashana, et al.
Publicado: (2019) -
In Situ Gel Formation in Microporated Skin for Enhanced Topical Delivery of Niacinamide
por: Bhattaccharjee, Sonalika, et al.
Publicado: (2020) -
Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment
por: Nagai, Noriaki, et al.
Publicado: (2018) -
Formulation and Evaluation of the In Vitro Performance of Topical Dermatological Products Containing Diclofenac Sodium
por: Manian, Mahima, et al.
Publicado: (2022) -
Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges
por: Agrahari, Vivek, et al.
Publicado: (2022)